Teva settles Nuvigil litigation with Mylan - Yahoo Finance

Teva Pharmaceutical Industries Ltd. (TEVA), one of the world’s largest producers of pharmaceuticals, announces that it has settled patent infringement litigation regarding U.S. Patent Number 7,132,570 (the "'570 patent") with respect to Mylan ...

Teva Pharma (TEVA) Sees Weaker FY12 Sales, EPS - StreetInsider.com

COPAXONE of $3.8 billion-- TREANDA® of $580 million-- Women’s Health products of $500 million-- ProAir® HFA of $430 million-- QVAR® of $350 million-- PROVIGIL® of $420 million-- AZILECT® of $340 million-- NUVIGIL® of $300 million OTC net sales of ...

Teva Provides Updated 2012 Non-GAAP Financial Outlook; Updated 2012 Non-GAAP Diluted EPS of $5.30 to $5.40 - StreetInsider.com

COPAXONE® of $3.8 billion-- TREANDA® of $580 million-- Women’s Health products of $500 million-- ProAir® HFA of $430 million-- QVAR® of $350 million-- PROVIGIL® of $420 million-- AZILECT® of $340 million-- NUVIGIL® of $300 million -- OTC net sales ...

Wake up! 4 ways to become a morning person - CBS News

And other drugs, like Provigial and Nuvigil, promote wakefulness, which may also help reset your body's natural patterns. Talk to your own doctor about which of these, if any, may help you.

Persistent Daytime Sleepiness Common Despite Effective CPAP - familypracticenews.com

The two drugs most beneficial as adjunctive therapy for these patients are modafinil (Provigil) and armodafinil (Nuvigil). Both are approved by the Food and Drug Administration for the management of persistent sleepiness and fatigue in patients with sleep ...

Mixed Quarter from Teva - Yahoo Finance

Revenues benefited from the inclusion of Cephalon products – Provigil ($291 million), Treanda ($148 million) and Nuvigil ($84 million). Key branded product Copaxone posted global in-market sales of $941 billion, up 4%. Other products/segments ...

Strong growth at Teva as Yanai era ends - Chicago Tribune

The increase in branded products revenue was mainly due to the inclusion of Cephalon sales (mainly Provigil with $291 million in revenue, Treanda with $148 million and Nuvigil with $84 million). Most of Teva's major branded products also had strong revenue.

7 Diseases Big Pharma Hopes You Get in 2012 - Huffington Post

Ads for Provigil, a Schedule IV stimulant that treats EDS along with Nuvigil show a judge in his black robe, nodding out on the job with the headline "Struggling to Fight The Fog?" ("Yo! Your Honor! I'm trying to plead!") Of course, wakefulness agents ...